MC
PRCT icon

Matisse Capital’s Procept Biorobotics PRCT Stock Holding History

Matisse Capital’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
13,389
+53
+0.4% +$1.33K 0.12% 135
2026
Q1 		$334K Sell
13,336
-4,731
-26% -$133K 0.14% 134
2025
Q4 		$568K Sell
18,067
-2,203
-11% -$73.1K 0.25% 95
2025
Q3 		$723K Sell
20,270
-90
-0.4% -$4.11K 0.33% 82
2025
Q2 		$1.17M Buy
20,360
+2,040
+11% +$115K 0.55% 63
2025
Q1 		$1.07M Sell
18,320
-3,965
-18% -$271K 0.56% 59
2024
Q4 		$1.79M Buy
22,285
+11,817
+113% +$1.01M 0.91% 34
2024
Q3 		$839K Buy
+10,468
New +$744K 0.41% 77

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Matisse Capital's PRCT Position: Q2 2026 in Review

Matisse Capital increased its Procept Biorobotics (PRCT) stake by 0.4% in Q2 2026, buying an estimated $1.33K and bringing the position to 13,389 shares worth $302K. The position accounts for 0.12% of the portfolio, ranked #135.

Matisse Capital first reported a position in PRCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.79M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Matisse Capital held 13,389 shares of Procept Biorobotics worth $302K as of Q2 2026.
  • Matisse Capital bought 53 Procept Biorobotics shares in Q2 2026, an estimated $1.33K.
  • Procept Biorobotics made up 0.12% of Matisse Capital's portfolio in Q2 2026, its #135 holding.
  • Matisse Capital first reported a position in Procept Biorobotics in Q3 2024 and has held it in 8 quarters since.
  • Matisse Capital's Procept Biorobotics position peaked at $1.79M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Matisse Capital's 13F filing for Q2 2026, filed 12 Aug 2026.